Search details
1.
Embracing cancer complexity: Hallmarks of systemic disease.
Cell
; 187(7): 1589-1616, 2024 Mar 28.
Article
in English
| MEDLINE | ID: mdl-38552609
2.
The next big questions in cancer research.
Cell
; 186(8): 1523-1527, 2023 04 13.
Article
in English
| MEDLINE | ID: mdl-37059060
3.
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.
Cell
; 173(6): 1413-1425.e14, 2018 05 31.
Article
in English
| MEDLINE | ID: mdl-29754815
4.
How Much Longer Will We Put Up With $100,000 Cancer Drugs?
Cell
; 168(4): 579-583, 2017 02 09.
Article
in English
| MEDLINE | ID: mdl-28187281
5.
A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.
Cell
; 165(2): 317-30, 2016 Apr 07.
Article
in English
| MEDLINE | ID: mdl-27058664
6.
A missing link in genotype-directed cancer therapy.
Cell
; 151(3): 465-8, 2012 Oct 26.
Article
in English
| MEDLINE | ID: mdl-23101617
7.
MED12 controls the response to multiple cancer drugs through regulation of TGF-ß receptor signaling.
Cell
; 151(5): 937-50, 2012 Nov 21.
Article
in English
| MEDLINE | ID: mdl-23178117
8.
EGFR activation limits the response of liver cancer to lenvatinib.
Nature
; 595(7869): 730-734, 2021 07.
Article
in English
| MEDLINE | ID: mdl-34290403
9.
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers.
Proc Natl Acad Sci U S A
; 121(9): e2319492121, 2024 Feb 27.
Article
in English
| MEDLINE | ID: mdl-38377196
10.
The phosphatase inhibitor LB-100 creates neoantigens in colon cancer cells through perturbation of mRNA splicing.
EMBO Rep
; 25(5): 2220-2238, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38600345
11.
Dual Inhibition of CDK4/6 and XPO1 Induces Senescence With Acquired Vulnerability to CRBN-Based PROTAC Drugs.
Gastroenterology
; 166(6): 1130-1144.e8, 2024 06.
Article
in English
| MEDLINE | ID: mdl-38262581
12.
It's diagnostics, stupid.
Cell
; 141(1): 13-7, 2010 Apr 02.
Article
in English
| MEDLINE | ID: mdl-20371338
13.
Radical Sabbaticals.
Cell
; 163(4): 788-9, 2015 Nov 05.
Article
in English
| MEDLINE | ID: mdl-26544929
14.
NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.
Cell
; 142(2): 218-29, 2010 Jul 23.
Article
in English
| MEDLINE | ID: mdl-20655465
15.
Inducing and exploiting vulnerabilities for the treatment of liver cancer.
Nature
; 574(7777): 268-272, 2019 10.
Article
in English
| MEDLINE | ID: mdl-31578521
16.
Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy.
Angiogenesis
; 26(2): 279-293, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36459240
17.
RNAi Delivers Insights into Liver Cancer.
Cell
; 135(5): 793-5, 2008 Nov 28.
Article
in English
| MEDLINE | ID: mdl-19041743
18.
Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib.
Br J Cancer
; 124(1): 176-182, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33204026
19.
Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.
Oncologist
; 26(4): 290-e545, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33296125
20.
CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.
Gut
; 69(4): 727-736, 2020 04.
Article
in English
| MEDLINE | ID: mdl-31519701